Alimta (pemetrexed)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Alimta (pemetrexed), covering 2011-07-25 to 2025-08-21. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung [Phase 1]